Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting (SIMPLE)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Integrated Medical Development, LLC
Information provided by (Responsible Party):
Valeritas, Inc.
ClinicalTrials.gov Identifier:
NCT01326598
First received: March 3, 2011
Last updated: February 25, 2013
Last verified: February 2013

March 3, 2011
February 25, 2013
January 2012
March 2014   (final data collection date for primary outcome measure)
The primary objective is to compare change of average glycemic control as measured by A1C from baseline to the end of V-Go use for the whole cohort as well as each of the five categories of baseline treatment. [ Time Frame: 12 month ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01326598 on ClinicalTrials.gov Archive Site
  • Glycemic control is measured by the HbA1C from the beginning of the study to the end. [ Time Frame: 12 month ] [ Designated as safety issue: No ]
    To describe change of average glycemic control as measured by A1C from baseline to the particular time point of analysis irrespective of treatment, and to describe this change for subjects who are still treated with the V-Go and those who have switched to other therapies.
  • To describe the incidence of hypoglycemia in participants as measured by blood glucose of <70 mg/dl. [ Time Frame: 12 month ] [ Designated as safety issue: No ]
    Occurrence of hypoglycemia confirmed with self monitored plasma referenced glucose measurement <70 mg/dl.
  • Number of Participants with adverse events. [ Time Frame: 12 month ] [ Designated as safety issue: No ]
  • How well the participants follow their doctors prescriptions for diabetes care. [ Time Frame: 12 month ] [ Designated as safety issue: No ]
    To describe frequency of self monitoring plasma glucose with V-Go therapy
  • To describe insulin dose requirements from the beginning to the end of the study , and concomitant drugs to lower blood glucose. [ Time Frame: 12 month ] [ Designated as safety issue: No ]
    Some of the insulin dose requirement that will described are: starting dose, dose titration, basal rate selection, dose conversion from previous therapy.
  • To describe changes in participants' weight from the beginning to the end of the study. [ Time Frame: 12 month ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting
Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting: A Long-term, Prospective, Observational Registry (SIMPLE)

The aim of the present study is to observe glycemic control, dose requirements, hypoglycemia risk, other possible adverse effects and weight changes, as well as to compare these parameters to prior treatment when patients with type 2 diabetes are initiated and treated using V-Go during circumstances as close to normal clinical practice as possible.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
Device: V-Go™
Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
T2DM patients with A1C<7.0%
Intervention: Device: V-Go™
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
270
May 2014
March 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Diagnosed type 2 diabetes mellitus for at least 12 months.
  2. Must be and have been in stable treatment for at least a month within each of the following diabetes medication regimens:

    • OADs only,
    • OADs in combination with either exenatide, pramlintide, liraglutide (collectively termed "incretin mimetics") without receiving insulin,
    • Once or twice daily injection of an intermediate or long acting insulin (insulin NPH, insulin detemir or insulin glargine) with or without OADs and/or an incretin.
    • One to three daily injections of premix insulin (human insulin 70/30, insulin lispro 75/25 or insulin aspart 70/30) with or without OADs and/or an incretin.
    • Any insulin therapy with three or more insulin injections a day with or without OADs (MDI).
  3. Must be willing to self monitor glucose at least twice a day.
  4. The patient must be willing and able in the opinion of the investigator to try V-Go as therapy.
  5. Age between 21 and 80 years old, inclusive.
  6. A1C greater than or equal to 7.0%.

Exclusion Criteria:

  1. Acute infection with fever.
  2. Serum creatinine > 3.0 mg/dl if not on metformin, or if on metformin for females creatinine > 1.4 mg/dl, for males creatinine > 1.5 mg/dl within the last 6 months.
  3. Pregnancy, intention to become pregnant or failure to agree to use adequate contraceptive measures during the trial for females of current reproductive potential.Medically acceptable contraceptives include: (1) surgical sterilization (such as tubal ligation or hysterectomy), (2) approved hormonal contraceptives (pills, patches, implants, or injections), (3) barrier methods (condom, diaphragm) used with spermicide, or (4) intrauterine device (IUD). Contraceptive measures such as "Plan B™", for emergency use after unprotected sex, are not acceptable methods for routine use. A lifestyle of abstinence from sexual activity is an acceptable means of contraception. If currently abstinent, the subject must agree to use a double-barrier method as described above if they become sexually active during the study period.
  4. Any medical history of malignant melanoma or breast cancer.
  5. Medical history of any other cancers within the last five years except adequately treated basal cell carcinoma or cervical carcinoma in-situ.
  6. History of alcohol or drug abuse within the last year.
  7. Any medical condition that in the opinion of the investigator may preclude safe and successful completion of the trial.
  8. Participation in other clinical trials involving receipt of investigational drug that cannot be disclosed within the last 30 days.
  9. Unwillingness and/or inability to comply with study procedures.
  10. Require regular adjustments or modifications to the basal rate during a 24-hour period, or if the amount of insulin used at meals require adjustments of less-than 2-Unit increments.
  11. History of hypersensitivity or hyperreactivity to adhesives.
Both
21 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01326598
V4006
No
Valeritas, Inc.
Valeritas, Inc.
Integrated Medical Development, LLC
Principal Investigator: Nancy J. Bohannon, MD Nancy J. Bohannon Med. Corp
Principal Investigator: David Huffman, MD University Diabetes & Endocrine Consultants
Principal Investigator: George Grunberger, MD Grunberger Diabetes Institute
Principal Investigator: Kenneth Hershon, MD North Shore Diabetes & Endocrine Assoc.
Principal Investigator: Chip Reed, MD Endocrine Research Solutions, Inc.
Principal Investigator: Cheryl Rosenfeld, DO North Jersey Endocrine Consultants, LLCAND
Principal Investigator: Alan B. Schorr, DO Alan B. Schorr, DO FACE
Principal Investigator: Mark Warren, MD Physicians East, PA
Principal Investigator: Richard A. Guthrie, MD MidAmerica Diabetes Associates
Principal Investigator: Lenita Hanson, MD MEDSOL Clinical Research Center
Principal Investigator: Philip A. Levin, MD MODEL Clinical Research
Principal Investigator: Michael Shanik, MD Endocrine Associates of Long Island, PC
Principal Investigator: Kathryn Jean Lucas, MD Diabetes & Endocrinology Consultants
Principal Investigator: Mary Katherine Lawrence, MD Down East Medical Associates
Principal Investigator: Sherry Sussman, MD Middle Country Endocrinology, P.C.
Principal Investigator: Robert Bernstein, MD Regional Endocrinology Associates, PC
Principal Investigator: Albert Johary, MD Albert Johary M.D., P.C.
Principal Investigator: Jeffrey Rothman, MD University Physicians Group
Principal Investigator: Robert Savino, DO Western Connecticut Health Network, Inc.
Principal Investigator: Sarah Khan, MD Parsippany Endocrine, LLC
Principal Investigator: Jonathan Wilson, DO PMG Research of Winston-Salem
Principal Investigator: Stephanie Powell, MD PMG Research of Bristol
Principal Investigator: Rickey Manning, MD PMG Research of Knoxville
Principal Investigator: Georges M. Argoud, MD San Diego Coastal Endocrinology Group
Valeritas, Inc.
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP